Robuta

To examine the role of the vanilloid receptor TRPV1 in neuropathic pain, we assessed the effects of the receptor antagonist thioxo-BCTC and antisense...

We have developed methods for verification of the structures of novel, chemically synthesized oligonucleotides having alternating...

Small interfering RNAs (siRNAs) hold significant promise as therapeutic agents for treating human diseases. However, their use is often limited by unintended...

Mitochondrial pyruvate dehydrogenase (mtPDH) is a key respiratory enzyme that links glycolysis and the tricarboxylic acid cycle, and it is negatively regulat...

Antisense Therapy Market is expected to reach USD 5.21 Billion by 2035, growing at a CAGR of 6.86% during the forecast period 2025-2035.

Genetic medicine could be revolutionized with new antisense oligonucleotide therapies like exosomes and nanoparticles.

The recent identification of antisense RNA in the transcriptomes of many eukaryotes has generated enormous interest. The presence of antisense RNA in...

Viltolarsen (NS-065/NCNP-01) has completed NDA to FDA O...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the disease.

Nov 26, 2025 - Global Antisense and RNAi Therapeutics Market size is expected to be worth around US$ 28.6 Billion by 2034 from US$ 5.2 Billion in 2024.